Key Takeaways
- Xen63 and Preserflo achieved similar 12-month surgical success rates and IOP reduction.
- Postoperative complications occurred significantly more often with Xen63 than with Preserflo.
- Reoperations were more frequent following Xen63 implantation, while intervention rates were similar between groups.
The Xen63 gel stent and Preserflo microshunt achieved similar intraocular pressure (IOP)-lowering outcomes and surgical success rates at 12 months in patients undergoing standalone glaucoma surgery with intraoperative mitomycin C, according to a study. However, Xen63 was associated with higher rates of postoperative complications and reoperations.
In the analysis of 140 eyes, 65 underwent Xen63 implantation and 75 received the Preserflo microshunt. Complete success, defined by sustained IOP control, at least a 20% reduction from baseline IOP, absence of clinical hypotony, and no need for glaucoma medications, was achieved in 61.5% of Xen63-treated eyes and 73.9% of Preserflo-treated eyes at 12 months (P = 0.13).
Both devices produced comparable reductions in IOP and postoperative medication burden. Postoperative intervention rates were 30.8% in Xen63 cases and 28.0% in Preserflo cases.
Postoperative complications were significantly more common in the Xen63 group than in the Preserflo group (61.5% and 29.3% of eyes, respectively; P = 0.0002). Reoperations were also performed more frequently following Xen63 implantation, with rates of 16.9% compared with 4.0% for Preserflo (p = 0.01).
Reference
De Francesco T, Zhang HA, Costa VP, et al. Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study. Clin Ophthalmol. 2026;20:603751. doi: 10.2147/OPTH.S603751. PMID: 42311276; PMCID: PMC13271431.
Related Content
